Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Janssen
PANKREASE HL® Capsules SCHEDULING STATUS: Schedule 1 PROPRIETARY NAME (and dosage form): PANKREASE HL ® Capsules COMPOSITION Each capsule contains Pancreatin equivalent to: Not less than: 25 000 BP units Lipase. 22 500 BP units Amylase 1 250 BP units Protease. PHARMACOLOGICAL CLASSIFICATION A.11.1. Medicines acting on the gastro-intestinal tract. Digestants. PHARMACOLOGICAL ACTION The enteric coated minitablets in PANKREASE HL resist gastric inactivation and deliver high levels of biologically active enzymes into the duodenum. The enzymes catalyse the hydrolysis of fats into glycerol and fatty acids, protein into proteases and derived substances, and starch into dextrins and sugars. INDICATIONS PANKREASE HL is indicated for patients with exocrine pancreatic enzyme deficiency as in: –cystic fibrosis –chronic pancreatitis –post-pancreatectomy. CONTRA-INDICATIONS PANKREASE HL is contra-indicated in patients known to be sensitive to pork protein. Reports have been received of skin rashes probably related to the above. Acute pancreatitis. Pregnancy: The safety of PANKREASE HL in pregnancy has not been established and such use is not recommended. DOSAGE AND DIRECTIONS FOR USE Adults and children: 1 or 2 capsules during each meal and 1 capsule with snacks. The individual response to pancreatin supplements is variable and the number of capsules may need to be titrated to the individual based upon parameters of steatorrhoea and symptomatology. Where patients are already in receipt of lower unit dose enteric coated pancreatin supplements, PANKREASE HL may be commenced at a dose relative to the lipase enzyme content of capsules normally consumed with the previous preparation, but it is important that the individuals response is monitored during the first weeks of therapy and dosage adjuste Read the complete document